REFERENCES
1. Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf [Last accessed on 17 Dec 2021].
2. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020;77:38-52.
3. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
4. Gupta S, Gupta A, Saini AK, Majumder K, Sinha K, Chahal A. Prostate cancer: how young is too young? Curr Urol 2017;9:212-5.
5. Lin PH, Aronson W, Freedland SJ. Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med 2015;13:3.
7. Matsushita M, Fujita K, Nonomura N. Influence of diet and nutrition on prostate cancer. Int J Mol Sci 2020;21:1447.
8. Lin PH, Aronson W, Freedland SJ. An update of research evidence on nutrition and prostate cancer. Urol Oncol 2019;37:387-401.
9. Leslie SW, Soon-Sutton TL, Sajjad H, Siref LE. Prostate cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
10. Lan T, Park Y, Colditz GA, et al. Adolescent dairy product and calcium intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study. Cancer Causes Control 2020;31:891-904.
11. Ganmaa D, Li X, Qin L, Wang P, Takeda M, Sato A. The experience of Japan as a clue to the etiology of testicular and prostatic cancers. Med Hypotheses 2003;60:724-30.
12. Qin LQ, Xu JY, Wang PY, Kaneko T, Hoshi K, Sato A. Milk consumption is a risk factor for prostate cancer: meta-analysis of case-control studies. Nutr Cancer 2004;48:22-7.
13. Qin LQ, Xu JY, Wang PY, Tong J, Hoshi K. Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. Asia Pac J Clin Nutr 2007;16:467-76.
14. Sargsyan A, Dubasi HB. Milk consumption and prostate cancer: a systematic review. World J Mens Health 2021;39:419-28.
15. Our world in data. Available from: https://ourworldindata.org/grapher/per-capita-milk-consumption [Last accessed on 17 Dec 2021].
16. Milchindustrie-Verband e.V: Deutschland: Pro-Kopfverbrauch von Milchprodukten. Available from: https://milchindustrie.de/wp-content/uploads/2020/04/ProkopfDeutschland_Mopro_2013-2019x_Homepage.pdf [Last accessed on 17 Dec 2021].
17. Ridder M. Statista: per capita consumption of milk in Sweden 2008-2018. Available from: https://www.statista.com/statistics/557618/per-capita-consumption-of-milk-in-sweden/ [Last accessed on 17 Dec 2021].
18. Statista. Per capita consumption of fluid milk products in the United States from 2000 to 2020 (in pounds)*. Available from: https://www.statista.com/statistics/184240/us-per-capita-consumption-of-fluid-milk- products/ [Last accessed on 17 Dec 2021].
19. Statista. Per capita milk and dairy product consumption in China from 2013 to 2020. Available from: https://www.statista.com/statistics/1098497/china-per-capita-milk-dairy-consumption/ [Last accessed on 17 Dec 2021].
20. Melnik BC. Milk-a nutrient system of mammalian evolution promoting mTORC1-dependent translation. Int J Mol Sci 2015;16:17048-87.
21. Melnik BC, John SM, Carrera-Bastos P, Cordain L. The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. Nutr Metab (Lond) 2012;9:74.
22. Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci 2020;21:4507.
23. Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev 2018;32:1105-40.
24. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19:575-86.
25. Crumbaker M, Khoja L, Joshua AM. AR signaling and the PI3K pathway in prostate cancer. Cancers (Basel) 2017;9:34.
26. Pearson HB, Li J, Meniel VS, et al. Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with pten loss to accelerate progression and castration-resistant growth. Cancer Discov 2018;8:764-79.
27. Chen H, Zhou L, Wu X, et al. The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci (Landmark Ed) 2016;21:1084-91.
28. Turnham DJ, Bullock N, Dass MS, Staffurth JN, Pearson HB. The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 2020;9:2342.
29. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000.
30. Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-9.
31. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998;4:811-5.
32. Rudge SA, Wakelam MJ. Phosphatidylinositolphosphate phosphatase activities and cancer. J Lipid Res 2016;57:176-92.
33. Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 2018;15:222-34.
34. Geybels MS, Fang M, Wright JL, et al. PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. Oncotarget 2017;8:84338-48.
35. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-6.
36. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
37. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
38. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28.
39. Armenia J, Wankowicz SAM, Liu D, et al. PCF/SU2C International Prostate Cancer Dream Team. The long tail of oncogenic drivers in prostate cancer. Nat Genet 2018;50:645-51.
40. Abida W, Cyrta J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A 2019;116:11428-36.
41. Liu P, Li S, Gan L, Kao TP, Huang H. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res 2008;68:10290-9.
42. Ma Q, Fu W, Li P, et al. FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol 2009;23:213-25.
43. Bohrer LR, Liu P, Zhong J, et al. FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate 2013;73:1017-27.
44. Zhao Y, Tindall DJ, Huang H. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci 2014;10:614-9.
45. Yan Y, Huang H. Interplay among PI3K/AKT, PTEN/FOXO and AR signaling in prostate cancer. Adv Exp Med Biol 2019;1210:319-31.
46. Wang Q, Bailey CG, Ng C, et al. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 2011;71:7525-36.
47. Millward DJ, Layman DK, Tomé D, Schaafsma G. Protein quality assessment: impact of expanding understanding of protein and amino acid needs for optimal health. Am J Clin Nutr 2008;87:1576S-81S.
48. Souci SW, Fachmann W, Kraut H. Food composition and nutrition tables. 8th revised and extended edition. Volume XXXII. Stuttgart, Germany: MedPharm; 2016. p. 1263.
49. Salisbury TB, Arthur S. The regulation and function of the L-type amino acid transporter 1 (LAT1) in cancer. Int J Mol Sci 2018;19:2373.
50. Zhang BK, Moran AM, Bailey CG, Rasko JEJ, Holst J, Wang Q. EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer. Cell Commun Signal 2019;17:83.
51. Otsuki H, Kimura T, Yamaga T, Kosaka T, Suehiro JI, Sakurai H. Prostate cancer cells in different androgen receptor status employ different leucine transporters. Prostate 2017;77:222-33.
52. Strmiska V, Michalek P, Eckschlager T, et al. Prostate cancer-specific hallmarks of amino acids metabolism: towards a paradigm of precision medicine. Biochim Biophys Acta Rev Cancer 2019;1871:248-58.
53. Zhang H, Pan Y, Zheng L, et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011;71:3257-67.
54. Ge C, Zhao G, Li Y, et al. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene 2016;35:366-76.
55. Akech J, Wixted JJ, Bedard K, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010;29:811-21.
56. Kim B, Kim H, Jung S, et al. A CTGF-RUNX2-RANKL axis in breast and prostate cancer cells promotes tumor progression in bone. J Bone Miner Res 2020;35:155-66.
57. Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
58. Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 2014;16:378-86.
59. Zabala-letona A, Arruabarrena-aristorena A, Martín-martín N, et al. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature 2017;547:109-13.
60. Audet-Walsh É, Vernier M, Yee T, et al. SREBF1 activity is regulated by an AR/mTOR nuclear axis in prostate cancer. Mol Cancer Res 2018;16:1396-405.
61. Han Y, Liu C, Zhang D, et al. Mechanosensitive ion channel Piezo1 promotes prostate cancer development through the activation of the Akt/mTOR pathway and acceleration of cell cycle. Int J Oncol 2019;55:629-44.
62. Binal Z, Açıkgöz E, Kızılay F, Öktem G, Altay B. Cross-talk between ribosome biogenesis, translation, and mTOR in CD133+ 4/CD44+ prostate cancer stem cells. Clin Transl Oncol 2020;22:1040-8.
63. Ngollo M, Dagdemir A, Karsli-Ceppioglu S, et al. Epigenetic modifications in prostate cancer. Epigenomics 2014;6:415-26.
64. Liao Y, Xu K. Epigenetic regulation of prostate cancer: the theories and the clinical implications. Asian J Androl 2019;21:279-90.
65. Zhu KC, Lu JJ, Xu XL, Sun JM. MicroRNAs in androgen-dependent PCa. Front Biosci (Landmark Ed) 2013;18:748-55.
66. Eringyte I, Zamarbide Losada JN, Powell SM, Bevan CL, Fletcher CE. Coordinated AR and microRNA regulation in prostate cancer. Asian J Urol 2020;7:233-50.
67. Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S. MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Lett 2017;407:9-20.
68. Verma S, Pandey M, Shukla GC, Singh V, Gupta S. Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer. PLoS One 2019;14:e0224071.
69. Folini M, Gandellini P, Longoni N, et al. miR-21: an oncomir on strike in prostate cancer. Mol Cancer 2010;9:12.
70. Ribas J, Lupold SE. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle 2010;9:923-9.
71. Yang Y, Guo JX, Shao ZQ. miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study. Asian Pac J Trop Med 2017;10:87-91.
72. Lu Z, Liu M, Stribinskis V, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008;27:4373-9.
73. Go H, Jang JY, Kim PJ, et al. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget 2015;6:15035-49.
74. Song W, Li Q, Wang L, Wang L. Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma. Cell Physiol Biochem 2015;35:184-90.
75. Shukla S, Shukla M, Maclennan GT, Fu P, Gupta S. Deregulation of FOXO3A during prostate cancer progression. Int J Oncol 2009;34:1613-20.
76. Wang K, Li PF. Foxo3a regulates apoptosis by negatively targeting miR-21. J Biol Chem 2010;285:16958-66.
77. Ribas J, Ni X, Haffner M, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009;69:7165-9.
78. Foj L, Ferrer F, Serra M, et al. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis. Prostate 2017;77:573-83.
79. Shin S, Park YH, Jung SH, et al. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer. NPJ Genom Med 2021;6:45.
80. Danarto R, Astuti I, Umbas R, Haryana SM. Urine miR-21-5p and miR-200c-3p as potential non-invasive biomarkers in patients with prostate cancer. Turk J Urol 2020;46:26-30.
81. Ghorbanmehr N, Gharbi S, Korsching E, Tavallaei M, Einollahi B, Mowla SJ. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer. Prostate 2019;79:88-95.
82. Zhou H, Zhu X. MicroRNA-21 and microRNA-30c as diagnostic biomarkers for prostate cancer: a meta-analysis. Cancer Manag Res 2019;11:2039-50.
83. Huang W, Kang XL, Cen S, Wang Y, Chen X. High-level expression of microRNA-21 in peripheral blood mononuclear cells is a diagnostic and prognostic marker in prostate cancer. Genet Test Mol Biomarkers 2015;19:469-75.
84. Zedan AH, Blavnsfeldt SG, Hansen TF, et al. Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations. PLoS One 2017;12:e0179113.
85. Sharma N, Baruah MM. The microRNA signatures: aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol 2019;21:126-44.
86. Arisan ED, Rencuzogullari O, Freitas IL, et al. Upregulated Wnt-11 and miR-21 expression trigger epithelial mesenchymal transition in aggressive prostate cancer cells. Biology (Basel) 2020;9:52.
87. Guan C, Zhang L, Wang S, et al. Upregulation of microRNA-21 promotes tumorigenesis of prostate cancer cells by targeting KLF5. Cancer Biol Ther 2019;20:1149-61.
89. Mishra S, Lin CL, Huang TH, Bouamar H, Sun LZ. MicroRNA-21 inhibits p57Kip2 expression in prostate cancer. Mol Cancer 2014;13:212.
90. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009;383:280-5.
91. Mishra S, Deng JJ, Gowda PS, et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene 2014;33:4097-106.
92. Yang CH, Pfeffer SR, Sims M, et al. The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis. J Biol Chem 2015;290:6037-46.
93. Reis ST, Pontes-Junior J, Antunes AA, et al. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol 2012;12:14.
94. Porzycki P, Ciszkowicz E, Semik M, Tyrka M. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int Urol Nephrol 2018;50:1619-26.
95. Hatano K, Fujita K. Extracellular vesicles in prostate cancer: a narrative review. Transl Androl Urol 2021;10:1890-907.
96. Szczyrba J, Löprich E, Wach S, et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 2010;8:529-38.
97. Dybos SA, Flatberg A, Halgunset J, et al. Increased levels of serum miR-148a-3p are associated with prostate cancer. APMIS 2018;126:722-31.
98. Gurbuz V, Sozen S, Bilen CY, Konac E. miR-148a, miR-152 and miR-200b promote prostate cancer metastasis by targeting DNMT1 and PTEN expression. Oncol Lett 2021;22:805.
99. Murata T, Takayama K, Katayama S, et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 2010;13:356-61.
100. Jalava SE, Urbanucci A, Latonen L, et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 2012;31:4460-71.
101. Hamilton MP, Rajapakshe KI, Bader DA, et al. The landscape of microRNA targeting in prostate cancer defined by AGO-PAR-CLIP. Neoplasia 2016;18:356-70.
102. Zhu Z, He X, Johnson C, et al. PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein. Biochem Biophys Res Commun 2007;358:66-72.
103. Valdez CD, Kunju L, Daignault S, Wojno KJ, Day ML. The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer. Prostate 2013;73:1776-85.
104. Sengupta D, Deb M, Patra SK. Antagonistic activities of miR-148a and DNMT1: ectopic expression of miR-148a impairs DNMT1 mRNA and dwindle cell proliferation and survival. Gene 2018;660:68-79.
105. Lee E, Wang J, Yumoto K, et al. DNMT1 regulates epithelial-mesenchymal transition and cancer stem cells, which promotes prostate cancer metastasis. Neoplasia 2016;18:553-66.
106. He H, Cai M, Zhu J, et al. miR-148a-3p promotes rabbit preadipocyte differentiation by targeting PTEN. In Vitro Cell Dev Biol Anim 2018;54:241-9.
107. Qingjuan L, Xiaojuan F, Wei Z, et al. miR-148a-3p overexpression contributes to glomerular cell proliferation by targeting PTEN in lupus nephritis. Am J Physiol Cell Physiol 2016;310:C470-8.
108. Jin X, Hao Z, Zhao M, et al. MicroRNA-148a regulates the proliferation and differentiation of ovine preadipocytes by targeting PTEN. Animals (Basel) 2021;11:820.
109. Pan W, Zhu S, Yuan M, et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 2010;184:6773-81.
110. Yang A, Sun Y, Gao Y, et al. Reciprocal regulation between miR-148a/152 and DNA methyltransferase 1 is associated with hyperhomocysteinemia-accelerated atherosclerosis. DNA Cell Biol 2017;36:462-74.
111. Kuroda A, Rauch TA, Todorov I, et al. Insulin gene expression is regulated by DNA methylation. PLoS One 2009;4:e6953.
112. Ouni M, Gunes Y, Belot MP, Castell AL, Fradin D, Bougnères P. The IGF1 P2 promoter is an epigenetic QTL for circulating IGF1 and human growth. Clin Epigenetics 2015;7:22.
113. Ouni M, Castell AL, Rothenbuhler A, Linglart A, Bougnères P. Higher methylation of the IGF1 P2 promoter is associated with idiopathic short stature. Clin Endocrinol (Oxf) 2016;84:216-21.
114. Chen J, Ying Y, Zhu H, et al. Curcumin-induced promoter hypermethylation of the mammalian target of rapamycin gene in multiple myeloma cells. Oncol Lett 2019;17:1108-14.
115. Rock CL. Milk and the risk and progression of cancer. Nestle Nutr Workshop Ser Pediatr Program 2011;67:173-85.
116. Manuelian CL, Penasa M, Visentin G, Zidi A, Cassandro M, De Marchi M. Mineral composition of cow milk from multibreed herds. Anim Sci J 2018;89:1622-7.
117. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr 2001;74:549-54.
118. Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 2005;97:1768-77.
119. Rodriguez C, McCullough ML, Mondul AM, et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev 2003;12:597-603.
120. Hayes RB, Ziegler RG, Gridley G, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999;8:25-34.
121. Berndt SI, Carter H, Landis PK, et al. Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology 2002;60:1118-23.
122. Aune D, Navarro Rosenblatt DA, Chan DS, et al. Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. Am J Clin Nutr 2015;101:87-117.
123. Maly IV, Hofmann WA. Fatty acids and calcium regulation in prostate cancer. Nutrients 2018;10:788.
124. Maly IV, Hofmann WA. Calcium and nuclear signaling in prostate cancer. Int J Mol Sci 2018;19:1237.
125. Harrison S, Lennon R, Holly J, et al. Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? Cancer Causes Control 2017;28:497-528.
126. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-8.
127. Cohen P, Peehl DM, Rosenfeld R. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1998;78:554-6.
128. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-5.
129. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59:2203-9.
130. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999;51 Suppl 3:34-41.
131. Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 2000;3:157-72.
132. Chokkalingam AP, Pollak M, Fillmore CM, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001;10:421-7.
133. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61:6276-80.
134. Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001;85:991-6.
135. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? Cancer Res 2003;63:3991-4.
136. Roberts CT. IGF-1 and prostate cancer. IGF-1 and prostate cancer. Novartis Found Symp 2004;262:193-9.
137. Renehan AG, Zwahlen M, Minder C, O'dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
138. Krueckl SL, Sikes RA, Edlund NM, et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64:8620-9.
139. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12.
140. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16:255-62.
141. Gennigens C, Menetrier-Caux C, Droz JP. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006;58:124-45.
142. Kawada M, Inoue H, Masuda T, Ikeda D. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res 2006;66:4419-25.
143. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006;99:392-401.
144. Kawada M, Inoue H, Arakawa M, Ikeda D. Transforming growth factor-beta1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I. Anticancer Res 2008;28:721-30.
145. Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 2009;16:161-7.
146. Nimptsch K, Platz EA, Pollak MN, et al. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. Int J Cancer 2011;128:660-7.
147. Heidegger I, Massoner P, Sampson N, Klocker H. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. Cancer Lett 2015;367:113-21.
148. Cao Y, Nimptsch K, Shui IM, et al. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer 2015;136:2418-26.
149. Ahearn TU, Peisch S, Pettersson A, et al. Transdisciplinary Prostate Cancer Partnership (ToPCaP). Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis 2018;39:1431-7.
150. Kim M, Kim JW, Kim JK, et al. Association between serum levels of insulin-like growth factor-1, bioavailable testosterone, and pathologic Gleason score. Cancer Med 2018;7:4170-80.
151. Ohishi T, Abe H, Sakashita C, et al. Inhibition of mitochondria ATP synthase suppresses prostate cancer growth through reduced insulin-like growth factor-1 secretion by prostate stromal cells. Int J Cancer 2020;146:3474-84.
152. Melnik BC, John SM, Schmitz G. Milk is not just food but most likely a genetic transfection system activating mTORC1 signaling for postnatal growth. Nutr J 2013;12:103.
153. Melnik BC, Schmitz G. Milk's role as an epigenetic regulator in health and disease. Diseases 2017;5:12.
154. Vasconcelos A, Santos T, Ravasco P, Neves PM. Dairy products: is there an impact on promotion of prostate cancer? Front Nutr 2019;6:62.
155. Pereira PC. Milk nutritional composition and its role in human health. Nutrition 2014;30:619-27.
156. Tunick MH, Van Hekken DL. Dairy products and health: recent insights. J Agric Food Chem 2015;63:9381-8.
157. Thorning TK, Raben A, Tholstrup T, Soedamah-Muthu SS, Givens I, Astrup A. Milk and dairy products: good or bad for human health? Food Nutr Res 2016;60:32527.
158. Gil Á, Ortega RM. Introduction and executive summary of the supplement, role of milk and dairy products in health and prevention of noncommunicable chronic diseases: a series of systematic reviews. Adv Nutr 2019;10:S67-73.
159. Timon CM, O'Connor A, Bhargava N, Gibney ER, Feeney EL. Dairy consumption and metabolic health. Nutrients 2020;12:3040.
160. Melnik BC. Lifetime impact of Cow's milk on overactivation of mTORC1: from fetal to childhood overgrowth, acne, diabetes, cancers, and neurodegeneration. Biomolecules 2021;11:404.
162. Michaëlsson K, Wolk A, Langenskiöld S, et al. Milk intake and risk of mortality and fractures in women and men: cohort studies. BMJ 2014;349:g6015.
163. Tognon G, Nilsson LM, Shungin D, et al. Nonfermented milk and other dairy products: associations with all-cause mortality. Am J Clin Nutr 2017;105:1502-11.
164. Michaëlsson K, Wolk A, Melhus H, Byberg L. Milk, fruit and vegetable, and total antioxidant intakes in relation to mortality rates: cohort studies in women and men. Am J Epidemiol 2017;185:345-61.
165. Michaëlsson K, Byberg L. Mixing of apples and oranges in milk research: a cohort analysis of non-fermented milk intake and all-cause mortality. Nutrients 2020;12:1393.
166. Torniainen S, Hedelin M, Autio V, et al. Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and Finland. Cancer Epidemiol Biomarkers Prev 2007;16:956-61.
167. Agarwal MM, Rana SV, Mandal AK, et al. Lactose intolerance in prostate cancer patients: incidence and associated factors. Scand J Gastroenterol 2008;43:270-6.
168. Torfadottir JE, Steingrimsdottir L, Mucci L, et al. Milk intake in early life and risk of advanced prostate cancer. Am J Epidemiol 2012;175:144-53.
169. Pettersson A, Kasperzyk JL, Kenfield SA, et al. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. Cancer Epidemiol Biomarkers Prev 2012;21:428-36.
170. Song Y, Chavarro JE, Cao Y, et al. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr 2013;143:189-96.
171. Yang M, Kenfield SA, Van Blarigan EL, et al. Dairy intake after prostate cancer diagnosis in relation to disease-specific and total mortality. Int J Cancer 2015;137:2462-9.
172. Lu W, Chen H, Niu Y, Wu H, Xia D, Wu Y. Dairy products intake and cancer mortality risk: a meta-analysis of 11 population-based cohort studies. Nutr J 2016;15:91.
173. Downer MK, Batista JL, Mucci LA, et al. Dairy intake in relation to prostate cancer survival. Int J Cancer 2017;140:2060-9.
174. Steck SE, Omofuma OO, Su LJ, et al. Calcium, magnesium, and whole-milk intakes and high-aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Am J Clin Nutr 2018;107:799-807.
175. Tat D, Kenfield SA, Cowan JE, et al. Milk and other dairy foods in relation to prostate cancer recurrence: data from the cancer of the prostate strategic urologic research endeavor (CaPSURE™). Prostate 2018;78:32-9.
176. Gaard M, Tretli S, Løken EB. Dietary fat and the risk of breast cancer: a prospective study of 25,892 Norwegian women. Int J Cancer 1995;63:13-7.
177. Ronco AL, De Stéfani E, Dáttoli R. Dairy foods and risk of breast cancer: a case-control study in Montevideo, Uruguay. Eur J Cancer Prev 2002;11:457-63.
178. Wang F, Yu L, Wang F, et al. Risk factors for breast cancer in women residing in urban and rural areas of eastern China. J Int Med Res 2015;43:774-89.
179. Galván-Salazar HR, Arreola-Cruz A, Madrigal-Pérez D, et al. Association of milk and meat consumption with the development of breast cancer in a western Mexican population. Breast Care (Basel) 2015;10:393-6.
180. Ji J, Sundquist J, Sundquist K. Lactose intolerance and risk of lung, breast and ovarian cancers: aetiological clues from a population-based study in Sweden. Br J Cancer 2015;112:149-52.
181. McCann SE, Hays J, Baumgart CW, Weiss EH, Yao S, Ambrosone CB. Usual consumption of specific dairy foods is associated with breast cancer in the Roswell Park cancer institute data bank and biorepository. Curr Dev Nutr 2017;1:e000422.
182. Fraser GE, Jaceldo-Siegl K, Orlich M, Mashchak A, Sirirat R, Knutsen S. Dairy, soy, and risk of breast cancer: those confounded milks. Int J Epidemiol 2020;49:1526-37.
183. Kaluza J, Komatsu S, Lauriola M, et al. Long-term consumption of non-fermented and fermented dairy products and risk of breast cancer by estrogen receptor status - Population-based prospective cohort study. Clin Nutr 2021;40:1966-73.
184. Duarte-Salles T, Fedirko V, Stepien M, et al. Dairy products and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2014;135:1662-72.
185. Yang W, Sui J, Ma Y, et al. A prospective study of dairy product intake and the risk of hepatocellular carcinoma in U.S. men and women. Int J Cancer 2020;146:1241-9.
186. Wang XJ, Jiang CQ, Zhang WS, et al. Milk consumption and risk of mortality from all-cause, cardiovascular disease and cancer in older people. Clin Nutr 2020;39:3442-51.
188. Wang J, Li X, Zhang D. Dairy product consumption and risk of non-hodgkin lymphoma: a meta-analysis. Nutrients 2016;8:120.
189. Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev 2016;35:515-24.
190. Sharma VR, Gupta GK, Sharma AK, et al. PI3K/Akt/mTOR intracellular pathway and breast cancer: factors, mechanism and regulation. Curr Pharm Des 2017;23:1633-8.
191. Hare SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res 2017;7:383-404.
192. Liu J, Li HQ, Zhou FX, Yu JW, Sun L, Han ZH. Targeting the mTOR pathway in breast cancer. Tumour Biol 2017;39:1010428317710825.
193. Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 2018;25:392-401.
194. Butt G, Shahwar D, Qureshi MZ, et al. Role of mTORC1 and mTORC2 in breast cancer: therapeutic targeting of mTOR and its partners to overcome metastasis and drug resistance. Adv Exp Med Biol 2019;1152:283-92.
195. Sridharan S, Basu A. Distinct roles of mTOR targets S6K1 and S6K2 in breast cancer. Int J Mol Sci 2020;21:1199.
196. Xu BH, Li XX, Yang Y, et al. Aberrant amino acid signaling promotes growth and metastasis of hepatocellular carcinomas through Rab1A-dependent activation of mTORC1 by Rab1A. Oncotarget 2015;6:20813-28.
197. Ericksen RE, Lim SL, McDonnell E, et al. Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression. Cell Metab 2019;29:1151-65.e6.
198. Ericksen RE, Han W. Malignant manipulaTORs of metabolism: suppressing BCAA catabolism to enhance mTORC1 activity. Mol Cell Oncol 2019;6:1585171.
199. Akula SM, Abrams SL, Steelman LS, et al. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opin Ther Targets 2019;23:915-29.
200. Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci 2020;21:1266.
201. Xu ZZ, Xia ZG, Wang AH, et al. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann Hematol 2013;92:1351-8.
202. Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules 2014;19:14304-15.
203. Browne SH, Diaz-Perez JA, Preziosi M, et al. mTOR activity in AIDS-related diffuse large B-cell lymphoma. PLoS One 2017;12:e0170771.
204. Ricci JE, Chiche J. Metabolic reprogramming of non-Hodgkin's B-cell lymphomas and potential therapeutic strategies. Front Oncol 2018;8:556.
205. Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD. A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans 2013;41:906-12.
206. Ben-Sahra I, Manning BD. mTORC1 signaling and the metabolic control of cell growth. Curr Opin Cell Biol 2017;45:72-82.
207. Rabanal-Ruiz Y, Korolchuk VI. mTORC1 and nutrient homeostasis: the central role of the lysosome. Int J Mol Sci 2018;19:818.
209. Condon KJ, Sabatini DM. Nutrient regulation of mTORC1 at a glance. J Cell Sci 2019;132:jcs222570.
210. Zhu M, Wang XQ. Regulation of mTORC1 by small GTPases in response to nutrients. J Nutr 2020;150:1004-11.
212. Rich-Edwards JW, Ganmaa D, Pollak MN, et al. Milk consumption and the prepubertal somatotropic axis. Nutr J 2007;6:28.
213. Barrea L, Di Somma C, Macchia PE, et al. Influence of nutrition on somatotropic axis: milk consumption in adult individuals with moderate-severe obesity. Clin Nutr 2017;36:293-301.
214. Grimberg A, Cohen P. Growth hormone and prostate cancer: guilty by association? J Endocrinol Invest 1999;22:64-73.
215. Weiss-Messer E, Merom O, Adi A, et al. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol Cell Endocrinol 2004;220:109-23.
216. Bidosee M, Karry R, Weiss-Messer E, Barkey RJ. Regulation of growth hormone receptors in human prostate cancer cell lines. Mol Cell Endocrinol 2009;309:82-92.
217. Bidosee M, Karry R, Weiss-Messer E, Barkey RJ. Growth hormone affects gene expression and proliferation in human prostate cancer cells. Int J Androl 2011;34:124-37.
218. Nakonechnaya AO, Shewchuk BM. Growth hormone enhances LNCaP prostate cancer cell motility. Endocr Res 2015;40:97-105.
220. Lin S, Li C, Li C, Zhang X. Growth hormone receptor mutations related to individual dwarfism. Int J Mol Sci 2018;19:1433.
221. Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res 2007;17:54-7.
222. Steuerman R, Shevah O, Laron Z. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol 2011;164:485-9.
223. Lapkina-Gendler L, Rotem I, Pasmanik-Chor M, et al. Identification of signaling pathways associated with cancer protection in Laron syndrome. Endocr Relat Cancer 2016;23:399-410.
224. Werner H, Sarfstein R, Nagaraj K, Laron Z. Laron syndrome research paves the way for new insights in oncological investigation. Cells 2020;9:2446.
225. Wang Z, Prins GS, Coschigano KT, et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 2005;146:5188-96.
226. Wang Z, Luque RM, Kineman RD, et al. Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat. Endocrinology 2008;149:1366-76.
227. Muñoz-Moreno L, Schally AV, Prieto JC, Carmena MJ, Bajo AM. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. Prostate 2018;78:915-26.
228. Recouvreux MV, Wu JB, Gao AC, et al. Androgen receptor regulation of local growth hormone in prostate cancer cells. Endocrinology 2017;158:2255-68.
229. Rogers I, Emmett P, Gunnell D, Dunger D, Holly J. ALSPAC Study Tteam. Milk as a food for growth? Public Health Nutr 2006;9:359-68.
230. Norat T, Dossus L, Rinaldi S, et al. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. Eur J Clin Nutr 2007;61:91-8.
231. Crowe FL, Key TJ, Allen NE, et al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2009;18:1333-40.
232. Qin LQ, He K, Xu JY. Milk consumption and circulating insulin-like growth factor-I level: a systematic literature review. Int J Food Sci Nutr 2009;60 Suppl 7:330-40.
233. Srinivasan V, Nimptsch K, Rohrmann S. Associations of current, childhood, and adolescent milk intake with serum insulin-like growth factor (IGF)-1 and IGF binding protein 3 concentrations in adulthood. Nutr Cancer 2019;71:931-8.
234. Romo Ventura E, Konigorski S, Rohrmann S, et al. Association of dietary intake of milk and dairy products with blood concentrations of insulin-like growth factor 1 (IGF-1) in Bavarian adults. Eur J Nutr 2020;59:1413-20.
235. Watling CZ, Kelly RK, Tong TYN, et al. Associations of circulating insulin-like growth factor-I with intake of dietary proteins and other macronutrients. Clin Nutr 2021;40:4685-93.
236. Hoppe C, Mølgaard C, Dalum C, Vaag A, Michaelsen KF. Differential effects of casein versus whey on fasting plasma levels of insulin, IGF-1 and IGF-1/IGFBP-3: results from a randomized 7-day supplementation study in prepubertal boys. Eur J Clin Nutr 2009;63:1076-83.
237. Blum JW, Baumrucker CR. Insulin-like growth factors (IGFs), IGF binding proteins, and other endocrine factors in milk: role in the newborn. Adv Exp Med Biol 2008;606:397-422.
238. Meyer Z, Höflich C, Wirthgen E, Olm S, Hammon HM, Hoeflich A. Analysis of the IGF-system in milk from farm animals - occurrence, regulation, and biomarker potential. Growth Horm IGF Res 2017;35:1-7.
239. Hoeflich A, Meyer Z. Functional analysis of the IGF-system in milk. Best Pract Res Clin Endocrinol Metab 2017;31:409-18.
240. Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC. Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J 1988;251:95-103.
241. Mauras N, Rogol AD, Haymond MW, Veldhuis JD. Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Horm Res 1996;45:74-80.
242. Benyi E, Sävendahl L. The physiology of childhood growth: hormonal regulation. Horm Res Paediatr 2017;88:6-14.
243. Bromek E, Rysz M, Haduch A, Daniel WA. Serotonin receptors of 5-HT2 type in the hypothalamic arcuate nuclei positively regulate liver cytochrome P450 via stimulation of the growth hormone-releasing hormone/growth hormone hormonal pathway. Drug Metab Dispos 2019;47:80-5.
244. Vottero A, Guzzetti C, Loche S. New aspects of the physiology of the GH-IGF-1 axis. Endocr Dev 2013;24:96-105.
245. Takahashi Y. The role of growth hormone and insulin-like growth factor-i in the liver. Int J Mol Sci 2017;18:1447.
246. Harp JB, Goldstein S, Phillips LS. Nutrition and somatomedin. XXIII. Molecular regulation of IGF-I by amino acid availability in cultured hepatocytes. Diabetes 1991;40:95-101.
247. Wheelhouse NM, Stubbs AK, Lomax MA, MacRae JC, Hazlerigg DG. Growth hormone and amino acid supply interact synergistically to control insulin-like growth factor-I production and gene expression in cultured ovine hepatocytes. J Endocrinol 1999;163:353-61.
248. Miller RA, Buehner G, Chang Y, Harper JM, Sigler R, Smith-Wheelock M. Methionine-deficient diet extends mouse lifespan, slows immune and lens aging, alters glucose, T4, IGF-I and insulin levels, and increases hepatocyte MIF levels and stress resistance. Aging Cell 2005;4:119-25.
249. Dukes A, Davis C, El Refaey M, et al. The aromatic amino acid tryptophan stimulates skeletal muscle IGF1/p70s6k/mTor signaling in vivo and the expression of myogenic genes in vitro. Nutrition 2015;31:1018-24.
250. Fleddermann M, Demmelmair H, Grote V, et al. Role of selected amino acids on plasma IGF-I concentration in infants. Eur J Nutr 2017;56:613-20.
251. Oh HS, Oh SK, Lee JS, Wu C, Lee SJ. Effects of l-arginine on growth hormone and insulin-like growth factor 1. Food Sci Biotechnol 2017;26:1749-54.
252. Tsugawa Y, Handa H, Imai T. Arginine induces IGF-1 secretion from the endoplasmic reticulum. Biochem Biophys Res Commun 2019;514:1128-32.
253. Li B, Hock A, Wu RY, et al. Bovine milk-derived exosomes enhance goblet cell activity and prevent the development of experimental necrotizing enterocolitis. PLoS One 2019;14:e0211431.
254. Argon Y, Bresson SE, Marzec MT, Grimberg A. Glucose-regulated protein 94 (GRP94): a novel regulator of insulin-like growth factor production. Cells 2020;9:1844.
255. Ghiasi SM, Dahlby T, Hede Andersen C, et al. Endoplasmic reticulum chaperone glucose-regulated protein 94 is essential for proinsulin handling. Diabetes 2019;68:747-60.
256. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90.
257. Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 2010;285:14071-7.
258. Menon S, Dibble CC, Talbott G, et al. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 2014;156:771-85.
259. Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol 2015;25:545-55.
260. Johnson SC. Nutrient sensing, signaling and ageing: the role of IGF-1 and mTOR in ageing and age-related disease. Subcell Biochem 2018;90:49-97.
261. Hoppe C, Mølgaard C, Michaelsen KF. Cow's milk and linear growth in industrialized and developing countries. Annu Rev Nutr 2006;26:131-73.
262. Mølgaard C, Larnkjær A, Arnberg K, Michaelsen KF. Milk and growth in children: effects of whey and casein. Nestle Nutr Workshop Ser Pediatr Program 2011;67:67-78.
263. Wiley AS. Cow milk consumption, insulin-like growth factor-I, and human biology: a life history approach. Am J Hum Biol 2012;24:130-8.
264. Martin RM, Holly JM, Gunnell D. Milk and linear growth: programming of the IGF-I axis and implication for health in adulthood. Nestle Nutr Workshop Ser Pediatr Program 2011;67:79-97.
265. Hyun S. Body size regulation and insulin-like growth factor signaling. Cell Mol Life Sci 2013;70:2351-65.
266. Ostman EM, Liljeberg Elmståhl HG, Björck IM. Inconsistency between glycemic and insulinemic responses to regular and fermented milk products. Am J Clin Nutr 2001;74:96-100.
267. Hoyt G, Hickey MS, Cordain L. Dissociation of the glycaemic and insulinaemic responses to whole and skimmed milk. Br J Nutr 2005;93:175-7.
268. Power O, Hallihan A, Jakeman P. Human insulinotropic response to oral ingestion of native and hydrolysed whey protein. Amino Acids 2009;37:333-9.
269. Yang J, Chi Y, Burkhardt BR, Guan Y, Wolf BA. Leucine metabolism in regulation of insulin secretion from pancreatic beta cells. Nutr Rev 2010;68:270-9.
270. Boirie Y, Dangin M, Gachon P, Vasson MP, Maubois JL, Beaufrère B. Slow and fast dietary proteins differently modulate postprandial protein accretion. Proc Natl Acad Sci U S A 1997;94:14930-5.
271. Moore WT, Bowser SM, Fausnacht DW, Staley LL, Suh KS, Liu D. Beta cell function and the nutritional state: dietary factors that influence insulin secretion. Curr Diab Rep 2015;15:76.
272. Straus DS. Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev 1984;5:356-69.
273. Sandow J. Growth effects of insulin and insulin analogues. Arch Physiol Biochem 2009;115:72-85.
274. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
276. Tokarz VL, MacDonald PE, Klip A. The cell biology of systemic insulin function. J Cell Biol 2018;217:2273-89.
277. McGuire M, Beerman KA. Nutritional sciences: from fundamentals to food (with table of food composition booklet). 3rd ed. Boston, USA: Cengage Learning; 2018.
278. Lenders CM, Liu S, Wilmore DW, et al. Evaluation of a novel food composition database that includes glutamine and other amino acids derived from gene sequencing data. Eur J Clin Nutr 2009;63:1433-9.
279. Durán RV, Oppliger W, Robitaille AM, et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012;47:349-58.
281. Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab 2009;296:E592-602.
282. Kim SG, Buel GR, Blenis J. Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells 2013;35:463-73.
283. Jewell JL, Russell RC, Guan KL. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 2013;14:133-9.
285. Zheng X, Liang Y, He Q, et al. Current models of mammalian target of rapamycin complex 1 (mTORC1) activation by growth factors and amino acids. Int J Mol Sci 2014;15:20753-69.
286. Averous J, Lambert-Langlais S, Carraro V, et al. Requirement for lysosomal localization of mTOR for its activation differs between leucine and other amino acids. Cell Signal 2014;26:1918-27.
287. Oshiro N, Rapley J, Avruch J. Amino acids activate mammalian target of rapamycin (mTOR) complex 1 without changing Rag GTPase guanyl nucleotide charging. J Biol Chem 2014;289:2658-74.
288. Jewell JL, Kim YC, Russell RC, et al. Metabolism. Differential regulation of mTORC1 by leucine and glutamine. Science 2015;347:194-8.
289. Wang S, Tsun ZY, Wolfson RL, et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 2015;347:188-94.
290. Duan Y, Li F, Tan K, et al. Key mediators of intracellular amino acids signaling to mTORC1 activation. Amino Acids 2015;47:857-67.
292. Powis K, De Virgilio C. Conserved regulators of Rag GTPases orchestrate amino acid-dependent TORC1 signaling. Cell Discov 2016;2:15049.
293. Nicastro R, Sardu A, Panchaud N, De Virgilio C. The architecture of the rag GTPase signaling network. Biomolecules 2017;7:48.
294. Wolfson RL, Sabatini DM. The dawn of the age of amino acid sensors for the mTORC1 pathway. Cell Metab 2017;26:301-9.
295. Ramlaul K, Aylett CHS. Signal integration in the (m)TORC1 growth pathway. Front Biol (Beijing) 2018;13:237-62.
296. Li XZ, Yan XH. Sensors for the mTORC1 pathway regulated by amino acids. J Zhejiang Univ Sci B 2019;20:699-712.
297. Zhuang Y, Wang XX, He J, He S, Yin Y. Recent advances in understanding of amino acid signaling to mTORC1 activation. Front Biosci (Landmark Ed) 2019;24:971-82.
298. Meng D, Yang Q, Wang H, et al. Glutamine and asparagine activate mTORC1 independently of Rag GTPases. J Biol Chem 2020;295:2890-9.
299. Segev N, Hay N. Hijacking leucyl-tRNA synthetase for amino acid-dependent regulation of TORC1. Mol Cell 2012;46:4-6.
300. Bonfils G, Jaquenoud M, Bontron S, Ostrowicz C, Ungermann C, De Virgilio C. Leucyl-tRNA synthetase controls TORC1 via the EGO complex. Mol Cell 2012;46:105-10.
301. Han JM, Jeong SJ, Park MC, et al. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell 2012;149:410-24.
302. Yoon MS, Son K, Arauz E, Han JM, Kim S, Chen J. Leucyl-tRNA synthetase activates Vps34 in amino acid-sensing mTORC1 signaling. Cell Rep 2016;16:1510-7.
303. Choi H, Son JB, Kang J, et al. Leucine-induced localization of Leucyl-tRNA synthetase in lysosome membrane. Biochem Biophys Res Commun 2017;493:1129-35.
304. Kim JH, Lee C, Lee M, et al. Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction. Nat Commun 2017;8:732.
305. Lee M, Kim JH, Yoon I, et al. Coordination of the leucine-sensing Rag GTPase cycle by leucyl-tRNA synthetase in the mTORC1 signaling pathway. Proc Natl Acad Sci U S A 2018;115:E5279-88.
306. Yoon I, Nam M, Kim HK, et al. Glucose-dependent control of leucine metabolism by leucyl-tRNA synthetase 1. Science 2020;367:205-10.
307. Carroll B, Maetzel D, Maddocks OD, et al. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. Elife 2016;5:e11058.
308. Groenewoud MJ, Zwartkruis FJ. Rheb and Rags come together at the lysosome to activate mTORC1. Biochem Soc Trans 2013;41:951-5.
309. Jensen RG, Ferris AM, Lammi-keefe CJ, Henderson RA. Lipids of bovine and human milks: a comparison. J Dairy Sci 1990;73:223-40.
310. Qian L, Zhao A, Zhang Y, et al. Metabolomic approaches to explore chemical diversity of human breast-milk, formula milk and bovine milk. Int J Mol Sci 2016;17:2128.
311. Bourlieu C, Michalski MC. Structure-function relationship of the milk fat globule. Curr Opin Clin Nutr Metab Care 2015;18:118-27.
312. Bassingthwaighte JB, Noodleman L, van der Vusse G, Glatz JF. Modeling of palmitate transport in the heart. Mol Cell Biochem 1989;88:51-8.
313. Suiter C, Singha SK, Khalili R, Shariat-Madar Z. Free fatty acids: circulating contributors of metabolic syndrome. Cardiovasc Hematol Agents Med Chem 2018;16:20-34.
314. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009;196:65-80.
315. Carroll B, Dunlop EA. The lysosome: a crucial hub for AMPK and mTORC1 signalling. Biochem J 2017;474:1453-66.
316. Hardie DG, Lin SC. AMP-activated protein kinase - not just an energy sensor. F1000Res 2017;6:1724.
317. Kwon B, Querfurth HW. Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: reversal by oleate is similar to metformin. Biochimie 2015;118:141-50.
318. Yasuda M, Tanaka Y, Kume S, et al. Fatty acids are novel nutrient factors to regulate mTORC1 lysosomal localization and apoptosis in podocytes. Biochim Biophys Acta 2014;1842:1097-108.
319. Kumar S, Tikoo K. Independent role of PP2A and mTORc1 in palmitate induced podocyte death. Biochimie 2015;112:73-84.
320. Zhou YP, Wu R, Shen W, Yu HH, Yu SJ. Comparison of effects of oleic acid and palmitic acid on lipid deposition and mTOR/S6K1/SREBP-1c pathway in HepG2 cells. Zhonghua Gan Zang Bing Za Zhi 2018;26:451-6.
321. Tang NT, D Snook R, Brown MD, et al. Fatty-acid uptake in prostate cancer cells using dynamic microfluidic raman technology. Molecules 2020;25:1652.
322. Kurahashi N, Inoue M, Iwasaki M, Sasazuki S, Tsugane AS. Japan Public Health Center-Based Prospective Study Group. Dairy product, saturated fatty acid, and calcium intake and prostate cancer in a prospective cohort of Japanese men. Cancer Epidemiol Biomarkers Prev 2008;17:930-7.
323. Preble I, Zhang Z, Kopp R, et al. Dairy product consumption and prostate cancer risk in the United States. Nutrients 2019;11:1615.
324. Li H, Xu W, Ma Y, Zhou S, Xiao R. Milk fat globule membrane protein promotes C2C12 cell proliferation through the PI3K/Akt signaling pathway. Int J Biol Macromol 2018;114:1305-14.
325. Li H, Guan K, Li X, Ma Y, Zhou S. MFG-E8 induced differences in proteomic profiles in mouse C2C12 cells and its effect on PI3K/Akt and ERK signal pathways. Int J Biol Macromol 2019;124:681-8.
326. Jinushi M, Nakazaki Y, Carrasco DR, et al. Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment. Cancer Res 2008;68:8889-98.
327. Soki FN, Koh AJ, Jones JD, et al. Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. J Biol Chem 2014;289:24560-72.
328. Rikkert LG, de Rond L, van Dam A, et al. Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging. PLoS One 2020;15:e0233443.
329. Reinhardt TA, Lippolis JD, Nonnecke BJ, Sacco RE. Bovine milk exosome proteome. J Proteomics 2012;75:1486-92.
330. Yamauchi M, Shimizu K, Rahman M, et al. Efficient method for isolation of exosomes from raw bovine milk. Drug Dev Ind Pharm 2019;45:359-64.
331. Rahman MM, Shimizu K, Yamauchi M, et al. Acidification effects on isolation of extracellular vesicles from bovine milk. PLoS One 2019;14:e0222613.
332. Munagala R, Aqil F, Jeyabalan J, Gupta RC. Bovine milk-derived exosomes for drug delivery. Cancer Lett 2016;371:48-61.
333. Khalifeh-Soltani A, McKleroy W, Sakuma S, et al. Mfge8 promotes obesity by mediating the uptake of dietary fats and serum fatty acids. Nat Med 2014;20:175-83.
334. Datta R, Lizama CO, Soltani AK, et al. Autoregulation of insulin receptor signaling through MFGE8 and the αvβ5 integrin. Proc Natl Acad Sci U S A 2021;118:e2102171118.
335. Heß K, Böger C, Behrens HM, Röcken C. Correlation between the expression of integrins in prostate cancer and clinical outcome in 1284 patients. Ann Diagn Pathol 2014;18:343-50.
336. Sun LC, Luo J, Mackey LV, Fuselier JA, Coy DH. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett 2007;246:157-66.
337. Welton JL, Brennan P, Gurney M, et al. Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array. J Extracell Vesicles 2016;5:31209.
338. Lough AK. The phytanic acid content of the lipids of bovine tissues and milk. Lipids 1977;12:115-9.
339. Brown PJ, Mei G, Gibberd FB, et al. Diet and Refsum's disease. The determination of phytanic acid and phytol in certain foods and the application of this knowledge to the choice of suitable convenience foods for patients with Refsum's disease. J Hum Nutr Diet 1993;6:295-305.
340. Vetter W, Schröder M. Concentrations of phytanic acid and pristanic acid are higher in organic than in conventional dairy products from the German market. Food Chemistry 2010;119:746-52.
341. Roca-Saavedra P, Mariño-Lorenzo P, Miranda JM, et al. Phytanic acid consumption and human health, risks, benefits and future trends: a review. Food Chem 2017;221:237-47.
342. Wright ME, Bowen P, Virtamo J, Albanes D, Gann PH. Estimated phytanic acid intake and prostate cancer risk: a prospective cohort study. Int J Cancer 2012;131:1396-406.
343. Dhaunsi GS, Alsaeid M, Akhtar S. Phytanic acid attenuates insulin-like growth factor-1 activity via nitric oxide-mediated γ-secretase activation in rat aortic smooth muscle cells: possible implications for pathogenesis of infantile Refsum disease. Pediatr Res 2017;81:531-6.
344. Murakami D, Okamoto I, Nagano O, et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 2003;22:1511-6.
345. Okamoto I, Kawano Y, Tsuiki H, et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 1999;18:1435-46.
346. Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y. CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targets 2010;10:287-306.
347. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-5.
348. Miletti-González KE, Murphy K, Kumaran MN, et al. Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem 2012;287:18995-9007.
349. Xu H, Tian Y, Yuan X, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther 2015;8:3783-92.
350. Lai CJ, Lin CY, Liao WY, Hour TC, Wang HD, Chuu CP. CD44 promotes migration and invasion of docetaxel-resistant prostate cancer cells likely via induction of hippo-yap signaling. Cells 2019;8:295.
351. Tsao T, Beretov J, Ni J, et al. Cancer stem cells in prostate cancer radioresistance. Cancer Lett 2019;465:94-104.
352. Okamoto I, Kawano Y, Murakami D, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 2001;155:755-62.
353. Senbanjo LT, AlJohani H, Majumdar S, Chellaiah MA. Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells. Cell Commun Signal 2019;17:80.
354. van der Deen M, Akech J, Wang T, et al. The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem 2010;109:828-37.
355. Fowler M, Borazanci E, McGhee L, et al. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem 2006;97:1-17.
356. Little GH, Baniwal SK, Adisetiyo H, et al. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Res 2014;74:2857-68.
357. Schroeder TM, Jensen ED, Westendorf JJ. Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today 2005;75:213-25.
358. Baniwal SK, Khalid O, Gabet Y, et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 2010;9:258.
359. Baier SR, Nguyen C, Xie F, Wood JR, Zempleni J. MicroRNAs are absorbed in biologically meaningful amounts from nutritionally relevant doses of cow milk and affect gene expression in peripheral blood mononuclear cells, HEK-293 kidney cell cultures, and mouse livers. J Nutr 2014;144:1495-500.
360. Price AJ, Allen NE, Appleby PN, et al. Plasma phytanic acid concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2010;91:1769-76.
361. Wright ME, Albanes D, Moser AB, et al. Serum phytanic and pristanic acid levels and prostate cancer risk in Finnish smokers. Cancer Med 2014;3:1562-9.
362. Xu J, Thornburg T, Turner AR, et al. Serum levels of phytanic acid are associated with prostate cancer risk. Prostate 2005;63:209-14.
363. Thornburg T, Turner AR, Chen YQ, Vitolins M, Chang B, Xu J. Phytanic acid, AMACR and prostate cancer risk. Future Oncol 2006;2:213-23.
364. Hellgren LI. Phytanic acid--an overlooked bioactive fatty acid in dairy fat? Ann N Y Acad Sci 2010;1190:42-9.
365. Nóbrega M, Cilião HL, Souza MF, et al. Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer. Genet Mol Biol 2020;43:e20180329.
366. Kotova ES, Savochkina YA, Doludin YV, et al. Identification of clinically significant prostate cancer by combined PCA3 and AMACR mRNA detection in urine samples. Res Rep Urol 2020;12:403-13.
367. Lloyd MD, Darley DJ, Wierzbicki AS, Threadgill MD. Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage. FEBS J 2008;275:1089-102.
368. Kuefer R, Varambally S, Zhou M, et al. α-Methylacyl-CoA Racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002;161:841-8.
369. Rubin MA, Bismar TA, Andrén O, et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14:1424-32.
370. Barry M, Dhillon PK, Stampfer MJ, et al. α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. Prostate 2012;72:301-6.
371. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Prostate 2005;63:341-6.
372. Zha S, Ferdinandusse S, Denis S, et al. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 2003;63:7365-76.
373. Maruyama K, Oshima T, Ohyama K. Exposure to exogenous estrogen through intake of commercial milk produced from pregnant cows. Pediatr Int 2010;52:33-8.
374. Goyon A, Cai JZ, Kraehenbuehl K, Hartmann C, Shao B, Mottier P. Determination of steroid hormones in bovine milk by LC-MS/MS and their levels in Swiss Holstein cow milk. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2016;33:804-16.
375. Malekinejad H, Scherpenisse P, Bergwerff AA. Naturally occurring estrogens in processed milk and in raw milk (from gestated cows). J Agric Food Chem 2006;54:9785-91.
376. Tso J, Aga DS. A systematic investigation to optimize simultaneous extraction and liquid chromatography tandem mass spectrometry analysis of estrogens and their conjugated metabolites in milk. J Chromatogr A 2010;1217:4784-95.
377. Kolok AS, Ali JM, Rogan EG, Bartelt-Hunt SL. The fate of synthetic and endogenous hormones used in the US beef and dairy industries and the potential for human exposure. Curr Environ Health Rep 2018;5:225-32.
378. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800-9.
379. Bandini M, Gandaglia G, Briganti A. Obesity and prostate cancer. Curr Opin Urol 2017;27:415-21.
380. Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab 1979;48:633-8.
381. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102:899-911.
382. Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS, Abern MR. Estrogens and prostate cancer. Prostate Cancer Prostatic Dis 2019;22:185-94.
383. Sehgal PD, Bauman TM, Nicholson TM, et al. Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer. Hum Pathol 2019;89:99-108.
384. Tong da Y, Wen XQ, Jin Y, et al. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide. Asian Pac J Cancer Prev 2010;11:1805-9.
385. Tong da Y, Wu Xy, Sun Hy, Jin Y, Liu Zw, Zhou Fj. Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide. Tumour Biol 2012;33:2151-8.
386. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009;55:533-42.
387. Bonkhoff H. Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. Prostate 2018;78:2-10.
388. Yu Z, Gao W, Jiang E, et al. Interaction between IGF-IR and ER induced by E2 and IGF-I. PLoS One 2013;8:e62642.
389. Lanzino M, Morelli C, Garofalo C, et al. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr Cancer Drug Targets 2008;8:597-610.
390. Hawsawi Y, El-Gendy R, Twelves C, Speirs V, Beattie J. Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis. Biochim Biophys Acta 2013;1836:345-53.
391. Sun L, Gao Z, Luo L, Tan H, Zhang G. Estrogen affects cell growth and IGF-1 receptor expression in renal cell carcinoma. Onco Targets Ther 2018;11:5873-8.
392. Pandini G, Genua M, Frasca F, Vigneri R, Belfiore A. Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway. Ann N Y Acad Sci 2009;1155:263-7.
393. Alayev A, Salamon RS, Berger SM, et al. mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation. Oncogene 2016;35:3535-43.
394. Migliaccio A, Castoria G, Di Domenico M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000;19:5406-17.
395. Mannella P, Brinton RD. Estrogen receptor protein interaction with phosphatidylinositol 3-kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1/2 in the same population of cortical neurons: a unified mechanism of estrogen action. J Neurosci 2006;26:9439-47.
396. Di Zazzo E, Galasso G, Giovannelli P, et al. Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget 2016;7:193-208.
397. Ohlsson JA, Johansson M, Hansson H, et al. Lactose, glucose and galactose content in milk, fermented milk and lactose-free milk products. Int Dairy J 2017;73:151-4.
398. Miles FL, Neuhouser ML, Zhang ZF. Concentrated sugars and incidence of prostate cancer in a prospective cohort. Br J Nutr 2018;120:703-10.
399. Marchesini G, Bua V, Brunori A, et al. Galactose elimination capacity and liver volume in aging man. Hepatology 1988;8:1079-83.
400. Schnegg M, Lauterburg BH. Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol 1986;3:164-71.
401. Cui X, Zuo P, Zhang Q, et al. Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J Neurosci Res 2006;84:647-54.
402. Sadigh-eteghad S, Majdi A, Mccann SK, et al. D-galactose-induced brain ageing model: a systematic review and meta-analysis on cognitive outcomes and oxidative stress indices. PLoS ONE 2017;12:e0184122.
403. Shwe T, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Role of D-galactose-induced brain aging and its potential used for therapeutic interventions. Exp Gerontol 2018;101:13-36.
404. Azman KF, Zakaria R. D-Galactose-induced accelerated aging model: an overview. Biogerontology 2019;20:763-82.
405. Shukla S, Srivastava JK, Shankar E, et al. Oxidative stress and antioxidant status in high-risk prostate cancer subjects. Diagnostics (Basel) 2020;10:126.
406. Chen L, Yao H, Chen X, et al. Ginsenoside Rg1 decreases oxidative stress and down-regulates AKT/mTOR signalling to attenuate cognitive impairment in mice and senescence of neural stem cells induced by D-Galactose. Neurochem Res 2018;43:430-40.
407. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68:1777-85.
408. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009;282:125-36.
409. Gupta-Elera G, Garrett AR, Robison RA, O'Neill KL. The role of oxidative stress in prostate cancer. Eur J Cancer Prev 2012;21:155-62.
410. Paschos A, Pandya R, Duivenvoorden WC, Pinthus JH. Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics. Prostate Cancer Prostatic Dis 2013;16:217-25.
411. Udensi UK, Tchounwou PB. Oxidative stress in prostate hyperplasia and carcinogenesis. J Exp Clin Cancer Res 2016;35:139.
412. Kaya E, Ozgok Y, Zor M, et al. Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: a prospective controlled study. Adv Clin Exp Med 2017;26:1095-9.
413. Zhang Z, Jiang D, Wang C, et al. Polymorphisms in oxidative stress pathway genes and prostate cancer risk. Cancer Causes Control 2019;30:1365-75.
414. Ahmed Amar SA, Eryilmaz R, Demir H, Aykan S, Demir C. Determination of oxidative stress levels and some antioxidant enzyme activities in prostate cancer. Aging Male 2019;22:198-206.
415. Zhao Y, Hu X, Liu Y, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer 2017;16:79.
416. Bei Y, Wu X, Cretoiu D, et al. miR-21 suppression prevents cardiac alterations induced by d-galactose and doxorubicin. J Mol Cell Cardiol 2018;115:130-41.
417. Jiao G, Pan B, Zhou Z, Zhou L, Li Z, Zhang Z. MicroRNA-21 regulates cell proliferation and apoptosis in H2O2-stimulated rat spinal cord neurons. Mol Med Rep 2015;12:7011-6.
418. Golan-Gerstl R, Elbaum Shiff Y, Moshayoff V, Schecter D, Leshkowitz D, Reif S. Characterization and biological function of milk-derived miRNAs. Mol Nutr Food Res 2017;61:1700009.
419. Howard KM, Jati Kusuma R, Baier SR, et al. Loss of miRNAs during processing and storage of cow's (Bos taurus) milk. J Agric Food Chem 2015;63:588-92.
420. Manca S, Upadhyaya B, Mutai E, et al. Milk exosomes are bioavailable and distinct microRNA cargos have unique tissue distribution patterns. Sci Rep 2018;8:11321.
421. Kirchner B, Pfaffl MW, Dumpler J, von Mutius E, Ege MJ. microRNA in native and processed cow's milk and its implication for the farm milk effect on asthma. J Allergy Clin Immunol 2016;137:1893-1895.e13.
422. Wang L, Sadri M, Giraud D, Zempleni J. RNase H2-dependent polymerase chain reaction and elimination of confounders in sample collection, storage, and analysis strengthen evidence that microRNAs in Bovine milk are bioavailable in humans. J Nutr 2018;148:153-9.
423. Özdemir S. Identification and comparison of exosomal microRNAs in the milk and colostrum of two different cow breeds. Gene 2020;743:144609.
424. Kleinjan M, van Herwijnen MJ, Libregts SF, van Neerven RJ, Feitsma AL, Wauben MH. Regular industrial processing of Bovine milk impacts the integrity and molecular composition of extracellular vesicles. J Nutr 2021;151:1416-25.
425. Yu S, Zhao Z, Sun L, Li P. Fermentation results in quantitative changes in milk-derived exosomes and different effects on cell growth and survival. J Agric Food Chem 2017;65:1220-8.
426. Melnik BC, Schmitz G. Pasteurized non-fermented cow's milk but not fermented milk is a promoter of mTORC1-driven aging and increased mortality. Ageing Res Rev 2021;67:101270.
427. Izumi H, Kosaka N, Shimizu T, Sekine K, Ochiya T, Takase M. Bovine milk contains microRNA and messenger RNA that are stable under degradative conditions. J Dairy Sci 2012;95:4831-41.
428. Benmoussa A, Lee CH, Laffont B, et al. Commercial dairy Cow Milk microRNAs resist digestion under simulated gastrointestinal tract conditions. J Nutr 2016;146:2206-15.
429. Kusuma RJ, Manca S, Friemel T, Sukreet S, Nguyen C, Zempleni J. Human vascular endothelial cells transport foreign exosomes from cow's milk by endocytosis. Am J Physiol Cell Physiol 2016;310:C800-7.
430. Melnik BC, Kakulas F, Geddes DT, et al. Milk miRNAs: simple nutrients or systemic functional regulators? Nutr Metab (Lond) 2016;13:42.
431. Rani P, Vashisht M, Golla N, Shandilya S, Onteru SK, Singh D. Milk miRNAs encapsulated in exosomes are stable to human digestion and permeable to intestinal barrier in vitro. J Funct Foods 2017;34:431-9.
432. Lönnerdal B. Human milk microRNAs/Exosomes: composition and biological effects. Composition and biological effects. Nestlé Nutr Inst Workshop Ser 2019;90:83-92.
433. Lin D, Chen T, Xie M, et al. Oral administration of bovine and porcine milk exosome alter miRNAs profiles in piglet serum. Sci Rep 2020;10:6983.
434. Benmoussa A, Provost P. Milk MIcroRNAs in health and disease. Compr Rev Food Sci Food Saf 2019;18:703-22.
435. Carrillo-Lozano E, Sebastián-Valles F, Knott-Torcal C. Circulating microRNAs in breast milk and their potential impact on the infant. Nutrients 2020;12:3066.
436. Chen Z, Xie Y, Luo J, et al. Milk exosome-derived miRNAs from water buffalo are implicated in immune response and metabolism process. BMC Vet Res 2020;16:123.
437. Sadri M, Shu J, Kachman SD, Cui J, Zempleni J. Milk exosomes and miRNA cross the placenta and promote embryo survival in mice. Reproduction 2020;160:501-9.
438. Reif S, Elbaum Shiff Y, Golan-Gerstl R. Milk-derived exosomes (MDEs) have a different biological effect on normal fetal colon epithelial cells compared to colon tumor cells in a miRNA-dependent manner. J Transl Med 2019;17:325.
439. Ozkan H, Tuzun F, Taheri S, et al. Epigenetic programming through breast milk and its impact on milk-siblings mating. Front Genet 2020;11:569232.
440. Jin Y, Kotler JLM, Wang S, Huang B, Halpin JC, Street TO. The ER chaperones BiP and Grp94 regulate the formation of insulin-like growth factor 2 (IGF2) oligomers. J Mol Biol 2021;433:166963.
441. Lu T, Wang Y, Xu K, et al. Co-downregulation of GRP78 and GRP94 induces apoptosis and inhibits migration in prostate cancer cells. Open Life Sci 2019;14:384-91.
442. Le Doare K, Holder B, Bassett A, Pannaraj PS. Mother's milk: a purposeful contribution to the development of the infant microbiota and immunity. Front Immunol 2018;9:361.
443. Melnik BC, Schmitz G. MicroRNAs: milk's epigenetic regulators. Best Pract Res Clin Endocrinol Metab 2017;31:427-42.
444. Stremmel W, Weiskirchen R, Melnik BC. Milk exosomes prevent intestinal inflammation in a genetic mouse model of ulcerative colitis: a pilot experiment. Inflamm Intest Dis 2020;5:117-23.
445. van Esch BCAM, Porbahaie M, Abbring S, et al. The impact of milk and its components on epigenetic programming of immune function in early life and beyond: implications for allergy and asthma. Front Immunol 2020;11:2141.
446. Zempleni J, Aguilar-Lozano A, Sadri M, et al. Biological activities of extracellular vesicles and their cargos from bovine and human milk in humans and implications for infants. J Nutr 2017;147:3-10.
447. Zempleni J, Sukreet S, Zhou F, Wu D, Mutai E. Milk-derived exosomes and metabolic regulation. Annu Rev Anim Biosci 2019;7:245-62.
448. Xie MY, Hou LJ, Sun JJ, et al. Porcine milk exosome miRNAS attenuate LPS-induced apoptosis through inhibiting TLR4/NF-κB and p53 pathways in intestinal epithelial cells. J Agric Food Chem 2019;67:9477-91.
449. Melnik BC, Stremmel W, Weiskirchen R, John SM, Schmitz G. Exosome-derived microRNAs of human milk and their effects on infant health and development. Biomolecules 2021;11:851.
450. Melnik BC, Schmitz G. Exosomes of pasteurized milk: potential pathogens of Western diseases. J Transl Med 2019;17:3.
451. Chen X, Gao C, Li H, et al. Identification and characterization of microRNAs in raw milk during different periods of lactation, commercial fluid, and powdered milk products. Cell Res 2010;20:1128-37.
452. Fromm B, Tosar JP, Lu Y, Halushka MK, Witwer KW. Human and cow have identical miR-21-5p and miR-30a-5p sequences, which are likely unsuited to study dietary uptake from cow milk. J Nutr 2018;148:1506-7.
453. miRBase. hsa-mir-21-5p nucleotide sequence. Available from: http://mirbase.org/cgi-bin/mirna_entry.pl?acc=MIMAT0000076 [Last accessed on 17 Dec 2021].
454. miRBase. bta-mir-21-5p nucleotide sequence. Available from: http://mirbase.org/cgi-bin/mirna_entry.pl?acc=MIMAT0003528 [Last accessed on 17 Dec 2021].
455. Arntz OJ, Pieters BC, Oliveira MC, et al. Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models. Mol Nutr Food Res 2015;59:1701-12.
456. Marquez RT, Bandyopadhyay S, Wendlandt EB, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010;90:1727-36.
457. de Ceuninck van Capelle C, Spit M, Ten Dijke P. Current perspectives on inhibitory SMAD7 in health and disease. Crit Rev Biochem Mol Biol 2020;55:691-715.
458. Li L, Jiang D. Hypoxia-responsive miRNA-21-5p inhibits Runx2 suppression by targeting SMAD7 in MC3T3-E1 cells. J Cell Biochem 2019;120:16867-75.
460. Xiong Y, Tang Y, Fan F, et al. Exosomal hsa-miR-21-5p derived from growth hormone-secreting pituitary adenoma promotes abnormal bone formation in acromegaly. Transl Res 2020;215:1-16.
461. Edlund S, Lee SY, Grimsby S, et al. Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol 2005;25:1475-88.
462. Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem 2005;96:484-9.
463. Vishal M, Swetha R, Thejaswini G, Arumugam B, Selvamurugan N. Role of Runx2 in breast cancer-mediated bone metastasis. Int J Biol Macromol 2017;99:608-14.
464. Do DN, Li R, Dudemaine PL, Ibeagha-Awemu EM. MicroRNA roles in signalling during lactation: an insight from differential expression, time course and pathway analyses of deep sequence data. Sci Rep 2017;7:44605.
465. Benmoussa A, Ly S, Shan ST, et al. A subset of extracellular vesicles carries the bulk of microRNAs in commercial dairy cow's milk. J Extracell Vesicles 2017;6:1401897.
466. Benmoussa A, Laugier J, Beauparlant CJ, Lambert M, Droit A, Provost P. Complexity of the microRNA transcriptome of cow milk and milk-derived extracellular vesicles isolated via differential ultracentrifugation. J Dairy Sci 2020;103:16-29.
467. Le Guillou S, Leduc A, Laubier J, et al. Characterization of Holstein and Normande whole milk miRNomes highlights breed specificities. Sci Rep 2019;9:20345.
468. van Herwijnen MJC, Driedonks TAP, Snoek BL, et al. Abundantly present miRNAs in milk-derived extracellular vesicles are conserved between mammals. Front Nutr 2018;5:81.
469. Braud M, Magee DA, Park SD, et al. Genome-wide microRNA binding site variation between extinct wild aurochs and modern cattle identifies candidate microRNA-regulated domestication genes. Front Genet 2017;8:3.
470. Do DN, Dudemaine PL, Li R, Ibeagha-Awemu EM. Co-expression network and pathway analyses reveal important modules of miRNAs regulating milk yield and component traits. Int J Mol Sci 2017;18:1560.
471. miRBase. hsa-mir-148a-3p nucleotide sequence. Available from: http://mirbase.org/cgi-bin/mirna_entry.pl?acc=MIMAT0000243 [Last accessed on 17 Dec 2021].
472. miRBase. bta-mir-148a-3p nucleotide sequence. Available from: http://mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0004737 [Last accessed on 17 Dec 2021].
473. Sanwlani R, Fonseka P, Chitti SV, Mathivanan S. Milk-derived extracellular vesicles in inter-organism, cross-species communication and drug delivery. Proteomes 2020;8:11.
474. Melnik BC, Kakulas F. Milk exosomes and microRNAs: potential epigenetic regulators. In: Patel V, Preedy V, editors. Handbook of nutrition, diet, and epigenetics. Cham: Springer International Publishing; 2017. p. 1-28.
475. Cao H, Wang L, Chen B, et al. DNA demethylation upregulated Nrf2 expression in Alzheimer's disease cellular model. Front Aging Neurosci 2015;7:244.
476. Bendavit G, Aboulkassim T, Hilmi K, Shah S, Batist G. Nrf2 transcription factor can directly regulate mTOR: linking cytoprotective gene expression to a major metabolic regulator that generates Redox activity. J Biol Chem 2016;291:25476-88.
477. Gao W, Ge S, Sun J. Ailanthone exerts anticancer effect by up-regulating miR-148a expression in MDA-MB-231 breast cancer cells and inhibiting proliferation, migration and invasion. Biomed Pharmacother 2019;109:1062-9.
478. TargetScanHuman, release 7.2. Available from: http://www.targetscan.org/cgi-bin/targetscan/vert_72/view_gene.cgi?rs=ENST00000287878.4&taxid=9606&members=miR-148-3p/152-3p&showcnc=0&shownc=0&shownc_nc=&showncf1=&showncf2=&subset=1 [Last accessed on 17 Dec 2021].
479. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214-26.
480. Oh S, Park MR, Son SJ, Kim Y. Comparison of total RNA isolation methods for analysis of immune-related microRNAs in market milks. Korean J Food Sci Anim Resour 2015;35:459-65.
481. Baddela VS, Nayan V, Rani P, Onteru SK, Singh D. Physicochemical biomolecular insights into buffalo milk-derived nanovesicles. Appl Biochem Biotechnol 2016;178:544-57.
482. El Tayebi HM, Waly AA, Assal RA, Hosny KA, Esmat G, Abdelaziz AI. Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncol Lett 2015;10:3206-12.
483. Sun JF, Zhang D, Gao CJ, Zhang YW, Dai QS. Exosome-mediated MiR-155 transfer contributes to hepatocellular carcinoma cell proliferation by targeting PTEN. Med Sci Monit Basic Res 2019;25:218-28.
484. Tang B, Lei B, Qi G, et al. MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression. J Exp Clin Cancer Res 2016;35:93.
485. Target ScanHuman. FBXW7 ENST00000281708.4. Available from: http://www.targetscan.org/cgibin/targetscan/vert_72/view_gene.cgi?rs=ENST00000281708.4&taxid=9606&members=&showcnc=0&shownc=0&showncf1=&showncf2=&subset=1 [Last accessed on 17 Dec 2021].
486. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321:1499-502.
487. Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer 2018;17:115.
488. Lan R, Jin B, Liu YZ, Zhang K, Niu T, You Z. Genome and transcriptome profiling of FBXW family in human prostate cancer. Am J Clin Exp Urol 2020;8:116-28.
489. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1:487-95.
490. Li R, Dudemaine PL, Zhao X, Lei C, Ibeagha-Awemu EM. Comparative analysis of the miRNome of Bovine milk fat, whey and cells. PLoS One 2016;11:e0154129.
491. Ammah AA, Do DN, Bissonnette N, Gévry N, Ibeagha-Awemu EM. Co-expression network analysis identifies miRNA-mRNA networks potentially regulating milk traits and blood metabolites. Int J Mol Sci 2018;19:2500.
492. Le MT, Teh C, Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009;23:862-76.
493. Kumar M, Lu Z, Takwi AA, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011;30:843-53.
494. Melnik BC. Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer. Nutr Metab (Lond) 2017;14:55.
495. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011;71:538-49.
496. Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One 2013;8:e61064.
497. Downing SR, Russell PJ, Jackson P. Alterations of p53 are common in early stage prostate cancer. Can J Urol 2003;10:1924-33.
498. Feng Z. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol 2010;2:a001057.
499. Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-9.
500. Feng Z, Hu W, de Stanchina E, et al. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 2007;67:3043-53.
501. Stambolic V, Macpherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell 2001;8:317-25.
502. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005;102:8204-9.
503. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006;20:267-75.
504. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. Expression of androgen receptor is negatively regulated by p53. Neoplasia 2007;9:1152-9.
505. Haupt S, Mejía-Hernández JO, Vijayakumaran R, Keam SP, Haupt Y. The long and the short of it: the MDM4 tail so far. J Mol Cell Biol 2019;11:231-44.
506. Stegeman S, Moya L, Selth LA, Spurdle AB, Clements JA, Batra J. A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer. Endocr Relat Cancer 2015;22:265-76.
507. Kotarac N, Dobrijevic Z, Matijasevic S, Savic-Pavicevic D, Brajuskovic G. Association of KLK3, VAMP8 and MDM4 genetic variants within microRNA binding sites with prostate cancer: evidence from Serbian population. Pathol Oncol Res 2020;26:2409-23.
508. Elmarakeby HA, Hwang J, Arafeh R, et al. Biologically informed deep neural network for prostate cancer discovery. Nature 2021;598:348-52.
509. Mecocci S, Pietrucci D, Milanesi M, et al. Transcriptomic characterization of cow, donkey and goat milk extracellular vesicles reveals their anti-inflammatory and immunomodulatory potential. Int J Mol Sci 2021;22:12759.
510. Correia NC, Gírio A, Antunes I, Martins LR, Barata JT. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer 2014;50:216-25.
511. Eguchi T, Watanabe K, Hara ES, Ono M, Kuboki T, Calderwood SK. OstemiR: a novel panel of microRNA biomarkers in osteoblastic and osteocytic differentiation from mesencymal stem cells. PLoS One 2013;8:e58796.
512. Wolf T, Baier SR, Zempleni J. The intestinal transport of bovine milk exosomes is mediated by endocytosis in human colon carcinoma Caco-2 cells and rat small intestinal IEC-6 cells. J Nutr 2015;145:2201-6.
513. Cicchini C, de Nonno V, Battistelli C, et al. Epigenetic control of EMT/MET dynamics: HNF4α impacts DNMT3s through miRs-29. Biochim Biophys Acta 2015;1849:919-29.
514. Bian Y, Lei Y, Wang C, et al. Epigenetic regulation of miR-29s affects the lactation activity of dairy cow mammary epithelial cells. J Cell Physiol 2015;230:2152-63.
515. Zhang J, Wang Y, Liu X, et al. Expression and potential role of microRNA-29b in mouse early embryo development. Cell Physiol Biochem 2015;35:1178-87.
516. Zhang Z, Cao Y, Zhai Y, et al. MicroRNA-29b regulates DNA methylation by targeting Dnmt3a/3b and Tet1/2/3 in porcine early embryo development. Dev Growth Differ 2018;60:197-204.
517. Mersey BD, Jin P, Danner DJ. Human microRNA (miR29b) expression controls the amount of branched chain alpha-ketoacid dehydrogenase complex in a cell. Hum Mol Genet 2005;14:3371-7.
518. Harris RA, Popov KM, Zhao Y, Shimomura Y. Regulation of branched-chain amino acid catabolism. J Nutr 1994;124:1499S-502S.
519. Doering CB, Williams IR, Danner DJ. Controlled overexpression of BCKD kinase expression: metabolic engineering applied to BCAA metabolism in a mammalian system. Metab Eng 2000;2:349-56.
520. Shimomura Y, Obayashi M, Murakami T, Harris RA. Regulation of branched-chain amino acid catabolism: nutritional and hormonal regulation of activity and expression of the branched-chain alpha-keto acid dehydrogenase kinase. Curr Opin Clin Nutr Metab Care 2001;4:419-23.
521. Nellis MM, Doering CB, Kasinski A, Danner DJ. Insulin increases branched-chain alpha-ketoacid dehydrogenase kinase expression in Clone 9 rat cells. Am J Physiol Endocrinol Metab 2002;283:E853-60.
522. Nie C, He T, Zhang W, Zhang G, Ma X. Branched chain amino acids: beyond nutrition metabolism. Int J Mol Sci 2018;19:954.
524. Worst TS, Previti C, Nitschke K, et al. miR-10a-5p and miR-29b-3p as extracellular vesicle-associated prostate cancer detection markers. Cancers (Basel) 2019;12:43.
525. Li Z, Hassan MQ, Jafferji M, et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 2009;284:15676-84.
526. Komori T. Regulation of proliferation, differentiation and functions of osteoblasts by Runx2. Int J Mol Sci 2019;20:1694.
528. Pratap J, Lian JB, Javed A, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006;25:589-600.
529. zur Hausen H, de Villiers EM. Dairy cattle serum and milk factors contributing to the risk of colon and breast cancers. Int J Cancer 2015;137:959-67.
530. Falida K, Eilebrecht S, Gunst K, Zur Hausen H, de Villiers EM. Isolation of two virus-like circular DNAs from commercially available milk samples. Genome Announc 2017;5:e00266-17.
531. zur Hausen H, Bund T, de Villiers E. Infectious agents in bovine red meat and milk and their potential role in cancer and other chronic diseases. Curr Top Microbiol Immunol 2017;407:83-116.
532. Eilebrecht S, Hotz-Wagenblatt A, Sarachaga V, et al. Expression and replication of virus-like circular DNA in human cells. Sci Rep 2018;8:2851.
533. Zur Hausen H, Bund T, de Villiers EM. Specific nutritional infections early in life as risk factors for human colon and breast cancers several decades later. Int J Cancer 2019;144:1574-83.
534. de Villiers EM, Gunst K, Chakraborty D, Ernst C, Bund T, Zur Hausen H. A specific class of infectious agents isolated from bovine serum and dairy products and peritumoral colon cancer tissue. Emerg Microbes Infect 2019;8:1205-18.
535. Bund T, Nikitina E, Chakraborty D, et al. Analysis of chronic inflammatory lesions of the colon for BMMF Rep antigen expression and CD68 macrophage interactions. Proc Natl Acad Sci U S A 2021;118:e2025830118.
536. de Villiers EM, Zur Hausen H. Bovine meat and milk factors (BMMFs): their proposed role in common human cancers and type 2 diabetes mellitus. Cancers (Basel) 2021;13:5407.
537. Prandini A, Tansini G, Sigolo S, Filippi L, Laporta M, Piva G. On the occurrence of aflatoxin M1 in milk and dairy products. Food Chem Toxicol 2009;47:984-91.
538. Ismail A, Akhtar S, Levin RE, Ismail T, Riaz M, Amir M. Aflatoxin M1: prevalence and decontamination strategies in milk and milk products. Crit Rev Microbiol 2016;42:418-27.
539. Hof H. Mycotoxins in milk for human nutrition: cow, sheep and human breast milk. GMS Infect Dis 2016;4:Doc03.
540. Marimón Sibaja KV, Gonçalves KDM, Garcia SO, et al. Aflatoxin M1 and B1 in Colombian milk powder and estimated risk exposure. Food Addit Contam Part B Surveill 2019;12:97-104.
541. Van der Fels-Klerx HJ, Vermeulen LC, Gavai AK, Liu C. Climate change impacts on aflatoxin B1 in maize and aflatoxin M1 in milk: a case study of maize grown in Eastern Europe and imported to the Netherlands. PLoS One 2019;14:e0218956.
542. Castegnaro M, Wild CP. IARC activities in mycotoxin research. Nat Toxins 1995;3:327-31; discussion 341.
543. IARC monographs on the identification of carcinogenic hazards to humans. Available from: https://monographs.iarc.fr/list-of-classifications (last updated 2020-03-03) [Last accessed on 17 Dec 2021].
544. Marchese S, Polo A, Ariano A, Velotto S, Costantini S, Severino L. Aflatoxin B1 and M1: biological properties and their involvement in cancer development. Toxins (Basel) 2018;10:214.
545. Vaz A, Cabral Silva AC, Rodrigues P, Venâncio A. Detection methods for aflatoxin M1 in dairy products. Microorganisms 2020;8:246.
546. Nguyen T, Flint S, Palmer J. Control of aflatoxin M1 in milk by novel methods: a review. Food Chem 2020;311:125984.
547. Scaglioni PT, Becker-Algeri T, Drunkler D, Badiale-Furlong E. Aflatoxin B1 and M1 in milk. Anal Chim Acta 2014;829:68-74.
548. Smith ER, Hagopian M. Uptake and secretion of carcinogenic chemicals by the dog and rat prostate. Prog Clin Biol Res 1981;75B:131-63.
549. Nishi N, Shoji H, Miyanaka H, Nakamura T. Androgen-regulated expression of a novel member of the aldo-keto reductase superfamily in regrowing rat prostate. Endocrinology 2000;141:3194-9.
550. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 2007;47:263-92.
551. Knight LP, Primiano T, Groopman JD, Kensler TW, Sutter TR. cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. Carcinogenesis 1999;20:1215-23.
552. Yepuru M, Wu Z, Kulkarni A, et al. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res 2013;19:5613-25.
553. Karunasinghe N, Ambs S, Wang A, et al. Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts. PLoS One 2018;13:e0199122.
554. Karunasinghe N, Symes E, Gamage A, et al. Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand. PLoS One 2019;14:e0217373.
555. Cui A, Hua H, Shao T, et al. Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration. Tumour Biol 2015;36:6507-13.
556. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36:177-84.
557. Posadas EM, Ahmed RS, Karrison T, et al. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: a University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate 2016;76:286-93.
558. Li W, Wang Z, Wang L, et al. Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med 2015;8:6563-7.
559. Chakraborty G, Patail NK, Hirani R, et al. Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors. Clin Cancer Res 2021;27:1792-806.
561. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol 2003;253:165-74.
562. Staack A, Donjacour AA, Brody J, Cunha GR, Carroll P. Mouse urogenital development: a practical approach. Differentiation 2003;71:402-13.
563. Thomson AA, Marker PC. Branching morphogenesis in the prostate gland and seminal vesicles. Differentiation 2006;74:382-92.
564. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 1999;140:1984-9.
565. Kleinberg DL, Ruan W, Yee D, Kovacs KT, Vidal S. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. Endocrinology 2007;148:1080-8.
566. Ohlson N, Bergh A, Persson ML, Wikström P. Castration rapidly decreases local insulin-like growth factor-1 levels and inhibits its effects in the ventral prostate in mice. Prostate 2006;66:1687-97.
567. Ohlsson C, Mohan S, Sjögren K, et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009;30:494-535.
568. Banjac L, Kotur-Stevuljević J, Gojković T, Bokan-Mirković V, Banjac G, Banjac G. Relationship between insulin-like growth factor type 1 and intrauterine growth. Acta Clin Croat 2020;59:91-6.
569. Singal SS, Nygard K, Gratton R, Jansson T, Gupta MB. Increased insulin-like growth factor binding protein-1 phosphorylation in decidualized stromal mesenchymal cells in human intrauterine growth restriction placentas. J Histochem Cytochem 2018;66:617-30.
570. Agrogiannis GD, Sifakis S, Patsouris ES, Konstantinidou AE. Insulin-like growth factors in embryonic and fetal growth and skeletal development (Review). Mol Med Rep 2014;10:579-84.
571. Ghosh S, Lau H, Simons BW, et al. PI3K/mTOR signaling regulates prostatic branching morphogenesis. Dev Biol 2011;360:329-42.
572. Li Y, Ge C, Franceschi RT. Role of Runx2 in prostate development and stem cell function. Prostate 2021;81:231-41.
573. Voerman E, Gaillard R, Geurtsen ML, Jaddoe VWV. Maternal first-trimester cow-milk intake is positively associated with childhood general and abdominal visceral fat mass and lean mass but not with other cardiometabolic risk factors at the age of 10 Years. J Nutr 2021;151:1965-75.
574. Roland MC, Friis CM, Voldner N, et al. Fetal growth versus birthweight: the role of placenta versus other determinants. PLoS One 2012;7:e39324.
575. Tibblin G, Eriksson M, Cnattingius S, Ekbom A. High birthweight as a predictor of prostate cancer risk. Epidemiology 1995;6:423-4.
576. Eriksson M, Wedel H, Wallander MA, et al. The impact of birth weight on prostate cancer incidence and mortality in a population-based study of men born in 1913 and followed up from 50 to 85 years of age. Prostate 2007;67:1247-54.
577. Zhou CK, Sutcliffe S, Welsh J, et al. Is birthweight associated with total and aggressive/lethal prostate cancer risks? Br J Cancer 2016;114:839-48.
578. Cnattingius S, Lundberg F, Sandin S, Grönberg H, Iliadou A. Birth characteristics and risk of prostate cancer: the contribution of genetic factors. Cancer Epidemiol Biomarkers Prev 2009;18:2422-6.
579. Lahmann PH, Wallström P, Lissner L, Olsson H, Gullberg B. Measures of birth size in relation to risk of prostate cancer: the Malmö Diet and Cancer Study, Sweden. J Dev Orig Health Dis 2012;3:442-9.
580. Heppe DH, van Dam RM, Willemsen SP, et al. Maternal milk consumption, fetal growth, and the risks of neonatal complications: the Generation R Study. Am J Clin Nutr 2011;94:501-9.
581. Olsen SF, Halldorsson TI, Willett WC, et al. NUTRIX Consortium. Milk consumption during pregnancy is associated with increased infant size at birth: prospective cohort study. Am J Clin Nutr 2007;86:1104-10.
582. Brantsæter AL, Olafsdottir AS, Forsum E, Olsen SF, Thorsdottir I. Does milk and dairy consumption during pregnancy influence fetal growth and infant birthweight? Food Nutr Res 2012;56:20050.
583. Melnik BC, John SM, Schmitz G. Milk consumption during pregnancy increases birth weight, a risk factor for the development of diseases of civilization. J Transl Med 2015;13:13.
584. Achón M, Úbeda N, García-González Á, Partearroyo T, Varela-Moreiras G. Effects of milk and dairy product consumption on pregnancy and lactation outcomes: a systematic review. Adv Nutr 2019;10:S74-87.
585. Jiang H, Wu W, Zhang M, et al. Aberrant upregulation of miR-21 in placental tissues of macrosomia. J Perinatol 2014;34:658-63.
586. Zhang JT, Cai QY, Ji SS, et al. Decreased miR-143 and increased miR-21 placental expression levels are associated with macrosomia. Mol Med Rep 2016;13:3273-80.
587. Wen HY, Abbasi S, Kellems RE, Xia Y. mTOR: a placental growth signaling sensor. Placenta 2005;26 Suppl A:S63-9.
588. Roos S, Lagerlöf O, Wennergren M, Powell TL, Jansson T. Regulation of amino acid transporters by glucose and growth factors in cultured primary human trophoblast cells is mediated by mTOR signaling. Am J Physiol Cell Physiol 2009;297:C723-31.
589. Jansson T, Aye IL, Goberdhan DC. The emerging role of mTORC1 signaling in placental nutrient-sensing. Placenta 2012;33 Suppl 2:e23-9.
590. Rosario FJ, Kanai Y, Powell TL, Jansson T. Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells. J Physiol 2013;591:609-25.
591. Xu J, Lu C, Wang J, Zhang R, Qian X, Zhu H. Regulation of human trophoblast GLUT3 glucose transporter by mammalian target of rapamycin signaling. Int J Mol Sci 2015;16:13815-28.
592. Rosario FJ, Powell TL, Gupta MB, Cox L, Jansson T. mTORC1 transcriptional regulation of ribosome subunits, protein synthesis, and molecular transport in primary human trophoblast cells. Front Cell Dev Biol 2020;8:583801.
593. Cook MB, Gamborg M, Aarestrup J, Sørensen TI, Baker JL. Childhood height and birth weight in relation to future prostate cancer risk: a cohort study based on the copenhagen school health records register. Cancer Epidemiol Biomarkers Prev 2013;22:2232-40.
594. Aarestrup J, Gamborg M, Cook MB, Baker JL. Childhood height increases the risk of prostate cancer mortality. Eur J Cancer 2015;51:1340-5.
595. Aarestrup J, Bjerregaard LG, Meyle KD, et al. Birthweight, childhood overweight, height and growth and adult cancer risks: a review of studies using the Copenhagen School Health Records Register. Int J Obes (Lond) 2020;44:1546-60.
596. Bjerregaard LG, Aarestrup J, Gamborg M, Lange T, Tjønneland A, Baker JL. Childhood height, adult height, and the risk of prostate cancer. Cancer Causes Control 2016;27:561-7.
597. Alimujiang A, Colditz GA, Gardner JD, Park Y, Berkey CS, Sutcliffe S. Childhood diet and growth in boys in relation to timing of puberty and adult height: the Longitudinal Studies of Child Health and Development. Cancer Causes Control 2018;29:915-26.
598. Wiley AS. Consumption of milk, but not other dairy products, is associated with height among US preschool children in NHANES 1999-2002. Ann Hum Biol 2009;36:125-38.
600. Almon R, Nilsson TK, Sjöström M, Engfeldt P. Lactase persistence and milk consumption are associated with body height in Swedish preadolescents and adolescents. Food Nutr Res 2011;55:7253.
601. Melnik BC. Evidence for acne-promoting effects of milk and other insulinotropic dairy products. Nestle Nutr Workshop Ser Pediatr Program 2011;67:131-45.
602. Adebamowo CA, Spiegelman D, Danby FW, Frazier AL, Willett WC, Holmes MD. High school dietary dairy intake and teenage acne. J Am Acad Dermatol 2005;52:207-14.
603. Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in adolescent girls. Dermatol Online J 2006:12.
604. Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in teenaged boys. J Am Acad Dermatol 2008;58:787-93.
605. Juhl CR, Bergholdt HKM, Miller IM, Jemec GBE, Kanters JK, Ellervik C. Dairy intake and acne vulgaris: a systematic review and meta-analysis of 78,529 children, adolescents, and young adults. Nutrients 2018;10:1049.
606. Aghasi M, Golzarand M, Shab-Bidar S, Aminianfar A, Omidian M, Taheri F. Dairy intake and acne development: a meta-analysis of observational studies. Clin Nutr 2019;38:1067-75.
607. Dai R, Hua W, Chen W, Xiong L, Li L. The effect of milk consumption on acne: a meta-analysis of observational studies. J Eur Acad Dermatol Venereol 2018;32:2244-53.
608. Robeva R, Assyov Y, Tomova A, Kumanov P. Acne vulgaris is associated with intensive pubertal development and altitude of residence-a cross-sectional population-based study on 6,200 boys. Eur J Pediatr 2013;172:465-71.
609. Melnik BC, Zouboulis CC. Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne. Exp Dermatol 2013;22:311-5.
610. Monfrecola G, Lembo S, Caiazzo G, et al. Mechanistic target of rapamycin (mTOR) expression is increased in acne patients' skin. Exp Dermatol 2016;25:153-5.
611. Agamia NF, Abdallah DM, Sorour O, Mourad B, Younan DN. Skin expression of mammalian target of rapamycin and forkhead box transcription factor O1, and serum insulin-like growth factor-1 in patients with acne vulgaris and their relationship with diet. Br J Dermatol 2016;174:1299-307.
612. Galobardes B, Davey Smith G, Jeffreys M, Kinra S, McCarron P. Acne in adolescence and cause-specific mortality: lower coronary heart disease but higher prostate cancer mortality: the Glasgow Alumni Cohort Study. Am J Epidemiol 2005;161:1094-101.
613. Sutcliffe S, Giovannucci E, Isaacs WB, Willett WC, Platz EA. Acne and risk of prostate cancer. Int J Cancer 2007;121:2688-92.
614. Ugge H, Udumyan R, Carlsson J, et al. Acne in late adolescence and risk of prostate cancer. Int J Cancer 2018;142:1580-5.
615. Tate PL, Bibb R, Larcom LL. Milk stimulates growth of prostate cancer cells in culture. Nutr Cancer 2011;63:1361-6.
616. Park SW, Kim JY, Kim YS, Lee SJ, Lee SD, Chung MK. A milk protein, casein, as a proliferation promoting factor in prostate cancer cells. World J Mens Health 2014;32:76-82.
617. Gordon WG, Semmett WF, Cable RS, Morris M. Amino acid composition of α-casein and β-casein2. J Am Chem Soc 1949;71:3293-7.
618. Kim JY, Bang SI, Lee SD. α-casein changes gene expression profiles and promotes tumorigenesis of prostate cancer cells. Nutr Cancer 2020;72:239-51.
619. Bernichtein S, Pigat N, Capiod T, et al. High milk consumption does not affect prostate tumor progression in two mouse models of benign and neoplastic lesions. PLoS One 2015;10:e0125423.
620. Larsson SC, Mason AM, Kar S, et al. Genetically proxied milk consumption and risk of colorectal, bladder, breast, and prostate cancer: a two-sample Mendelian randomization study. BMC Med 2020;18:370.
621. Clausnitzer J. Statista. Per capita consumption of milk in Finland 2010-2020. Available from: https://www.statista.com/statistics/460031/per-capita-consumption-of-milk-in-finland/ [Last accessed on 17 Dec 2021].
622. Vissers LET, Sluijs I, van der Schouw YT, et al. Dairy product intake and risk of type 2 diabetes in EPIC-interAct: a mendelian randomization study. Diabetes Care 2019;42:568-75.
623. Kitsiou-Tzeli S, Tzetis M. Maternal epigenetics and fetal and neonatal growth. Curr Opin Endocrinol Diabetes Obes 2017;24:43-6.
624. Cullen SM, Hassan N, Smith-Raska M. Effects of noninherited ancestral genotypes on offspring phenotypes†. Biol Reprod 2021;105:747-60.
625. Godos Godos J, Tieri M, Ghelfi F, et al. Dairy foods and health: an umbrella review of observational studies. Int J Food Sci Nutr 2020;71:138-51.
626. Cavero-Redondo I, Alvarez-Bueno C, Sotos-Prieto M, Gil A, Martinez-Vizcaino V, Ruiz JR. Milk and dairy product consumption and risk of mortality: an overview of systematic reviews and meta-analyses. Adv Nutr 2019;10:S97-S104.
627. López-Plaza B, Bermejo LM, Santurino C, Cavero-Redondo I, Álvarez-Bueno C, Gómez-Candela C. Milk and dairy product consumption and prostate cancer risk and mortality: an overview of systematic reviews and meta-analyses. Adv Nutr 2019;10:S212-23.
628. Ong SL, Blenkiron C, Haines S, et al. Ruminant milk-derived extracellular vesicles: a nutritional and therapeutic opportunity? Nutrients 2021;13:2505.
629. Zhang Y, Xu Q, Hou J, et al. Loss of bioactive microRNAs in cow's milk by ultra-high-temperature treatment but not by pasteurization treatment. J Sci Food Agric 2021; doi: 10.1002/jsfa.11607.
630. The American College of Obstreticians and Gynecologists. Nutrition during pregnancy. Available from: https://www.acog.org/womens-health/faqs/nutrition-during-pregnancy [Last accessed on 17 Dec 2021].
631. John Hopkins Medicine. Eating safely during pregnancy. Available from: https://www.hopkinsmedicine.org/health/wellness-and-prevention/-/media/ksw-images/eatingsafely [Last accessed on 17 Dec 2021].
633. Government UK. Guidance. Eligibility for the school milk subsidy scheme - milk consumed from 1 January 2021. Available from: https://www.gov.uk/guidance/eligibility-for-the-school-milk-subsidy-scheme-milk-consumed-from-1-january-2021 [Last accessed on 17 Dec 2021].
634. Agostoni C, Turck D. Is cow's milk harmful to a child's health? J Pediatr Gastroenterol Nutr 2011;53:594-600.
635. Everett S, Joshi R, Galmer L, Goolsby M, Lane J. Diet and nutrition in orthopedics. In: Rajendram R, Preedy VR, Patel VB, editors. Diet and nutrition in critical care. New York: Springer; 2014. p. 1-20.
636. Fardellone P, Séjourné A, Blain H, Cortet B, Thomas T. GRIO Scientific Committee. Osteoporosis: is milk a kindness or a curse? Joint Bone Spine 2017;84:275-81.
